New formulation of 5-fluorouracil in microspheres reduces toxicity in mice.

abstract：:Dihydroartemisinin (DHA), a semisynthetic derivative of artemisinin, has recently shown antitumor activity in various cancer cells. Its effect on pancreatic cancer is, however, unknown and the mechanism is unclear. The study aims to investigate its antitumor activity and underlying mechanisms in human pancreatic cance...

journal_title：Anti-cancer drugs

authors： Chen H,Sun B,Pan S,Jiang H,Sun X

更新日期：2009-02-01 00:00:00

abstract：:Targeting of cytotoxic agents represents a modern approach to the treatment of various cancers, that improves the efficacy and reduces peripheral toxicity. Recently we developed a powerful cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AN-207, designed to be targeted to tumors that express LHRH rece...

journal_title：Anti-cancer drugs

authors： Arencibia JM,Schally AV,Halmos G,Nagy A,Kiaris H

更新日期：2001-01-01 00:00:00

abstract：:The primary objective was to determine the optimal doses for gemcitabine (prolonged infusion), liposomal doxorubicin (Myocet) and docetaxel as primary (neoadjuvant) chemotherapy for locally advanced breast cancer. Secondary objectives included evaluation of the safety and efficacy of the regimen. Patients (n=19) with ...

journal_title：Anti-cancer drugs

authors： Schmid P,Krocker J,Schulz CO,Michniewicz K,Dieing A,Eggemann H,Heilmann V,Blohmer JU,Sezer O,Elling D,Possinger K

更新日期：2005-01-01 00:00:00

abstract：:Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl degrees). Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 an...

journal_title：Anti-cancer drugs

authors： Duffaud F,van der Burg ME,Namer M,Vergote I,Willemse PHB,ten Bokkel Huinink W,Guastalla JP,Nooij,Kerbrat P,Piccart M,Tumolo S,Favalli G,van der Vange N,Lacave AJ,Wils J,Splinter TA,Einhorn N,Roozendaal KJ,Rosso R,Ve

更新日期：2001-02-01 00:00:00

abstract：:PC cell-derived growth factor is a novel growth factor for tumor formation and progression. No comprehensive literature concerning PC cell-derived growth factor expression status and its biological function in squamous cell carcinoma, especially in the larynx, is, however, available. The target of this study is to eva...

journal_title：Anti-cancer drugs

authors： Kong WJ,Zhang SL,Chen X,Zhang S,Wang YJ,Zhang D,Sun Y

更新日期：2007-01-01 00:00:00

abstract：:The recombinant monoclonal antibody trastuzumab has antiproliferative effect on breast cancer (BC) cells with ErbB2 overexpression. We postulated that a mechanism able to modify ErbB2 expression enhances the antitumor effect of trastuzumab. We analyzed whether granulocyte-colony stimulating factor (G-CSF), widely used...

journal_title：Anti-cancer drugs

authors： Cavalloni G,Sarotto I,Pignochino Y,Gammaitoni L,Migliardi G,Sgro L,Piacibello W,Risio M,Aglietta M,Leone F

更新日期：2008-08-01 00:00:00

abstract：:Continuous exposure to daunorubicin (DNR) confers resistance against the drug-elicited lethality of leukemic cells and then reduces the remission rate. However, the detailed mechanisms involved in resistance development of leukemic cells to DNR remain unclear. Upregulation of aldo-keto reductases (AKRs) in human leuke...

journal_title：Anti-cancer drugs

authors： Matsunaga T,Yamaguchi A,Morikawa Y,Kezuka C,Takazawa H,Endo S,El-Kabbani O,Tajima K,Ikari A,Hara A

更新日期：2014-09-01 00:00:00

abstract：:The aim of this phase II study was to evaluate safety and efficacy of an oxaliplatin/vinorelbine/5-fluorouracil (FON) combination in anthracycline and taxane-pretreated metastatic breast cancer patients. The following treatment was given: on day 1 of a 21-day cycle, oxaliplatin 130 mg/m (2-h intravenous infusion); on ...

journal_title：Anti-cancer drugs

authors： Delozier T,Guastalla JP,Yovine A,Levy C,Chollet P,Mousseau M,Delva R,Coeffic D,Vannetzel JM,Zazzi ES,Brienza S,Cvitkovic E

更新日期：2006-10-01 00:00:00

abstract：:Protein phosphatase 2A (PP2A) is a new target for platinum (Pt)-based cancer chemotherapeutic agents. A series of novel Pt complexes containing demethylcantharidin, a modified component of a traditional Chinese medicine (TCM), [Pt(C8H8O5)(NH2R)2] 1-5 have been shown to inhibit PP2A both in its purified form and in cel...

journal_title：Anti-cancer drugs

authors： To KK,Ho YP,Au-Yeung SC

更新日期：2005-09-01 00:00:00

abstract：:It is well known that the anti-cancer drug cisplatin has an ototoxic property; however, the details are not yet evident. In this study, the expression of inducible nitric oxide synthase (INOS/NOS II) in the vestibule of guinea pigs after i.p. injections of cisplatin was examined immunohistochemically. Three days after...

journal_title：Anti-cancer drugs

authors： Watanabe K,Hess A,Bloch W,Michel O

更新日期：2000-01-01 00:00:00

abstract：:Anti-tubulin couplets have activity in hormone-resistant prostate cancer. This study was designed to define the dose-limiting toxicity (DLT) and recommended phase II dose (RPTD) of the unique triplet combination of paclitaxel, estramustine phosphate (EMP) and vinorelbine (Pacl-E-Vin). Patients with advanced malignanci...

journal_title：Anti-cancer drugs

authors： Sewak S,Chachoua A,Hamilton A,Taneja S,Lee J,Utate M,Sorich J,Muggia FM

更新日期：2003-01-01 00:00:00

abstract：:(E)-2'-deoxy-2'-(fluoromethylene) cytidine (MDL101,731) is a new deoxycytidine analog which shows potent antitumor activity against several human tumor models. We previously showed that MDL101,731 inhibited human ribonucleotide reductase (RNR) in HeLa S3 human cervical carcinoma cells. Recently, it has been reported t...

journal_title：Anti-cancer drugs

authors： Kanazawa J,Takahashi T,Akinaga S,Tamaoki T,Okabe M

更新日期：1998-08-01 00:00:00

abstract：:Twelve patients received intrapleural instilments of the cytostatic agent mitoxantrone in a total dosage of 30 mg for locoregional palliative therapy of malignant pleural effusion. Effusion could be stopped for a mean period of 3.2 months in 11 patients. ...

journal_title：Anti-cancer drugs

authors： Torsten U,Opri F,Weitzel H

更新日期：1992-02-01 00:00:00

abstract：:This study aims to investigate the significance and mechanism of artesunate involved in suppressing the proliferation of gastric cancer in vitro and in vivo. In the in-vitro experiments, artesunate inhibited the growth of gastric cancer cell lines (SGC-7901, BGC-823, and AGS) with concentration-dependent activity, wit...

journal_title：Anti-cancer drugs

authors： Zhou X,Sun WJ,Wang WM,Chen K,Zheng JH,Lu MD,Li PH,Zheng ZQ

更新日期：2013-10-01 00:00:00

abstract：:The prevalence of chronic myeloid leukemia and multiple myeloma has increased in recent years partly because of an improved therapeutic armamentarium for both conditions. Likewise, understanding the complexity inherent in designing combination treatment strategies will become increasingly prescient in the coming years...

journal_title：Anti-cancer drugs

authors： Katzel JA,Lee-Ma A,Vesole DH

更新日期：2015-09-01 00:00:00

abstract：:Amifostine is a broad-spectrum cytoprotective agent approved for protection against cisplatin toxicities and radiation-induced xerostomia; strong clinical evidence exists that amifostine protects normal mucosa and lung from radiation damage. Hypotension, nausea/vomiting, fatigue and fever/rash are the main side-effect...

journal_title：Anti-cancer drugs

authors： Koukourakis MI,Maltezos E

更新日期：2006-02-01 00:00:00

abstract：:In our institution, 103 glioblastoma multiforme (GBM) patients aged from 55 to 83 years were treated since November 1994 as follows. All patients underwent surgical intervention (gross total resection, n = 35; subtotal resection, n = 38; stereotactic biopsy, n = 30). Subsequently all patients were offered radiotherapy...

journal_title：Anti-cancer drugs

authors： Piribauer M,Fazeny-Dörner B,Rössler K,Ungersböck K,Czech T,Killer M,Dieckmann K,Birner P,Prayer D,Hainfellner J,Muhm M,Marosi C

更新日期：2003-02-01 00:00:00

abstract：:Organotypic cultures of human A549 cells were used as a tumor model to investigate sequence effects for combination treatments with adriamycin (ADR) and X-irradiation. Initial drug exposure led to the greatest cytotoxic effect especially when X-rays were delivered 24 h later and this subsequent irradiation did not sig...

journal_title：Anti-cancer drugs

authors： Chevillard S,Vielh P,Campana F,Bastian G,Coppey J

更新日期：1992-04-01 00:00:00

abstract：:Mantle cell lymphoma (MCL) remains incurable for most patients, and proteasome inhibitors like bortezomib induce responses in a minority of patients with relapsed disease. Fenretinide is a retinoid that has shown preclinical activity in B-cell lymphomas. We hypothesized that these agents could yield augmented antitumo...

journal_title：Anti-cancer drugs

authors： Cowan AJ,Frayo SL,Press OW,Palanca-Wessels MC,Pagel JM,Green DJ,Gopal AK

更新日期：2015-10-01 00:00:00

abstract：:Our study was to examine the roles of crizotinib and ceritinib in hepatocellular carcinoma (HCC) cells and explore the possible mechanisms. MTT assay was employed to examine the proliferation of five HCC cell lines treated with various concentrations of crizotinib or ceritinib. HepG2 and HCCLM3 cells were incubated wi...

journal_title：Anti-cancer drugs

authors： Yu Z,Zhao R

更新日期：2018-07-01 00:00:00

abstract：:In the past decade, tumour flare reaction (TFR) was considered as a new side effect associated with immunomodulatory agents (IMiDs) and as a condition of chronic lymphocytic leukaemia (CLL). However, this phenomenon is also observed with immune checkpoint inhibitors in solid tumours. It is still poorly understood and ...

journal_title：Anti-cancer drugs

authors： Taleb B A

更新日期：2019-10-01 00:00:00

abstract：:The extravasation of chemotherapeutic agents is a challenge for oncologic care teams. The management of nonliposomal (conventional) anthracyclines is well established in clinical practice guidelines, including general measures and specific antidotes, such as dexrazoxane. However, there is little scientific evidence on...

journal_title：Anti-cancer drugs

authors： Caballero Romero Á,Delgado Ureña MT,Salmerón García A,Megías Fernández MT,Librada Porriño-Bustamante M,Cabeza Barrera J

更新日期：2018-10-01 00:00:00

abstract：:We recruited 50 patients with T2-4 N0-2 M0 primary breast cancer into a phase I/II study to define the maximum tolerated dose (MTD), efficacy and tolerability of preoperative gemcitabine (1250 mg/m fixed dose) plus epirubicin (doses escalated from 90 mg/m) for 5 cycles followed by 4 cycles of docetaxel (scheduled fixe...

journal_title：Anti-cancer drugs

authors： Schneeweiss A,Schuetz F,Rudlowski C,Hahn M,Lauschner I,Sinn HP,von Fournier D,Sohn C

更新日期：2005-10-01 00:00:00

abstract：:Systemic chemotherapy for patients with a good performance status and advanced non-small cell lung cancer may result in prolonged survival and improved quality of life. However, few single agents have an activity of more than 15% and they have significant toxicity. Cisplatin is widely regarded as the single agent of c...

journal_title：Anti-cancer drugs

authors： Abratt RP

更新日期：1995-12-01 00:00:00

abstract：:Interleukin-12 (IL-12) has important immunomodulatory effects on T and natural killer (NK) cells that might be exploited in anticancer treatment. Murine IL-12 models have shown antimetastatic and antitumor effects against murine tumors in vivo. Data on the effects of human IL-12 on human tumors are confined to 51Cr-re...

journal_title：Anti-cancer drugs

authors： Izquierdo MA,Degen D,Sypek JP,Von Hoff DD

更新日期：1996-05-01 00:00:00

abstract：:The in-vitro growth inhibition of cancer and normal cell lines caused by mixed or covalently linked antimetabolites should clarify whether the conjugation of antimetabolites influences cell sensitivity and growth inhibition in a manner that differs from an equimolar mixture of the same antimetabolites or not. Growth i...

journal_title：Anti-cancer drugs

authors： Weinreich J,Struller F,Küper M,Hack A,Königsrainer A,Schott TC

更新日期：2013-04-01 00:00:00

abstract：:Tumor-to-tumor metastasis is a rare phenomenon, with around 150 cases being reported in the literature. Breast cancer is the second most commonly reported donor tumor after lung cancer, but thymic epithelial tumors have never been reported as recipient tumors. Furthermore, the thymus is rarely affected by metastases. ...

journal_title：Anti-cancer drugs

authors： Moretto R,Cella CA,Raimondo L,Formisano L,Nappi L,Rescigno P,Buonerba C,Calabrese F,Ottaviano M,Di Lorenzo G,Matano E,Damiano V,Palmieri G

更新日期：2013-08-01 00:00:00

abstract：:We evaluated economic implications of treatment with irinotecan, following a RCT which demonstrated significantly increased survival at 1 year with irinotecan (45%) compared to infusional 5-fluorouracil (5-FU) (32%) in patients with metastatic colorectal cancer. Medical care consumption data were collected prospective...

journal_title：Anti-cancer drugs

authors： Schmitt C,Blijham G,Jolain B,Rougier P,Van Cutsem E

更新日期：1999-07-01 00:00:00

abstract：:Patients with metastatic squamous cell cancer of the head and neck (SCCHN) have a poor prognosis, with most patients surviving less than a year. Immunotherapy (IO) is changing the natural history of the disease and programmed death-ligand 1 (PD-L1) inhibitors are showing notable improvements in survival with a more fa...

journal_title：Anti-cancer drugs

authors： Cabezas-Camarero S,Cabrera-Martín MN,Pérez-Segura P

更新日期：2019-02-01 00:00:00

abstract：:Different derivatives of nitrosoureas were synthesized by a long sequence of reactions and were evaluated for their anticancer activities against female Swiss albino mice, 6-8 weeks old, weighing 18-24 g and bearing Sarcoma-180 (S-180) ascitic tumor. Experimental protocols include injecting a total of 2 x 10(5) S-180 ...

journal_title：Anti-cancer drugs

authors： Nyati MK,Rajoria CM,Gupta RR,Dev PK

更新日期：1995-10-01 00:00:00